Even high-dose extended infusions may not yield desired concentrations of β-lactams: the value of therapeutic drug monitoring

Infectious Diseases
Menino Osbert CottaJeffrey Lipman

Abstract

A 35-year-old patient in intensive care with severe burn injury developed episodes of sepsis. Blood culture yielded a multidrug-resistant Pseudomonas aeruginosa and treatment was commenced with amikacin (minimum inhibitory concentration (MIC) 2-4 mg/L, dose 20 mg/kg adjusted body weight 24-hourly) and meropenem (MIC 8 mg/L, dose 2 g IV 8-hourly and later 6-hourly). Despite the use of extended infusions with β-lactam therapeutic drug monitoring and doses that were more than 2.5 times higher than standard meropenem doses, resistance emerged. This case report describes the application of therapeutic drug monitoring to optimize β-lactam therapy in a difficult-to-treat critically ill patient.

References

Nov 1, 1982·The Journal of Infectious Diseases·A U GerberW A Craig
Feb 10, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Craig
Jul 24, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J D Turnidge
Sep 3, 2002·The Journal of Antimicrobial Chemotherapy·Vincent H TamGeorge L Drusano
Apr 23, 2003·Burns : Journal of the International Society for Burn Injuries·Salah NasserAshraf Maher
Jun 5, 2003·The Journal of Trauma·John FitzwaterGrant E O'Keefe
Nov 24, 2005·Antimicrobial Agents and Chemotherapy·Vincent H TamElizabeth A Coyle
Feb 20, 2007·Antimicrobial Agents and Chemotherapy·Chonghua LiDavid P Nicolau
Sep 1, 2007·Current Opinion in Critical Care·Johan W Mouton, Alexander A Vinks
Nov 13, 2007·Burns : Journal of the International Society for Burn Injuries·Harvey ChimColin Song
Feb 25, 2009·Critical Care Medicine·Jason A Roberts, Jeffrey Lipman
Mar 13, 2012·Therapeutic Drug Monitoring·Bhavik M PatelJason A Roberts
Apr 24, 2012·Clinical and Experimental Pharmacology & Physiology·Mahipal G SinnollareddyJason A Roberts
Mar 2, 2013·Critical Care : the Official Journal of the Critical Care Forum·Andrew A UdyJeffrey Lipman
Jan 21, 2014·The Journal of Antimicrobial Chemotherapy·Gloria WongJason A Roberts

❮ Previous
Next ❯

Citations

Sep 30, 2015·Medicina intensiva·M O CottaJ Lipman
Mar 24, 2018·Drugs·A J HeffernanJ A Roberts
Jan 23, 2021·Pharmacotherapy·Andrew J FratoniJoseph L Kuti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.